Recent Quotes (30 days)

You have no recent quotes
chg | %

Merus Labs International Inc  

(Public, TSE:MSL)   Watch this stock  
Find more results for MSL
2.70
+0.07 (2.66%)
Mar 5 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.58 - 2.75
52 week 1.29 - 2.77
Open 2.63
Vol / Avg. 2.47M/221,718.00
Mkt cap 219.27M
P/E     -
Div/yield     -
EPS -0.10
Shares 81.21M
Beta 0.50
Inst. own     -
Feb 12, 2015
Q1 2015 Merus Labs International Inc Earnings Call
Feb 11, 2015
Q1 2015 Merus Labs International Inc Earnings Release
Dec 18, 2014
Q4 2014 Merus Labs International Inc Earnings Call
Dec 18, 2014
Q4 2014 Merus Labs International Inc Earnings Release
  

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -2.03% -30.83%
Operating margin 14.13% -15.01%
EBITD margin - 46.24%
Return on average assets -0.44% -5.65%
Return on average equity -0.83% -10.85%
Employees 6 -
CDP Score - -

Address

100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151
TORONTO, ON M5K 1H1
Canada
+1-416-5933701 (Phone)

Website links

Description

Merus Labs International Inc. (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women's health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Officers and directors

David D. Guebert CPA Independent Chairman of the Board
Barry Fishman Chief Executive Officer, Director
Ahmad Doroudian Executive Vice Chairman of the Board
Age: 50
Andrew Patient Chief Financial Officer
Ulrich Schoeberl Managing Director, European Operations
Theresa Sheila Firestone Director
Robert S. Pollock Independent Director
Timothy G. Sorensen Independent Director
Michael S. Cloutier Non-Executive Independent Director